vs
Emergent BioSolutions Inc.（EBS）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
Emergent BioSolutions Inc.的季度营收约是REPUBLIC BANCORP INC的1.6倍（$148.7M vs $94.3M），REPUBLIC BANCORP INC净利率更高（24.2% vs -36.7%，领先60.9%），REPUBLIC BANCORP INC同比增速更快（5.3% vs -23.6%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $73.8M），过去两年REPUBLIC BANCORP INC的营收复合增速更高（-11.5% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
EBS vs RBCAA — 直观对比
营收规模更大
EBS
是对方的1.6倍
$94.3M
营收增速更快
RBCAA
高出28.9%
-23.6%
净利率更高
RBCAA
高出60.9%
-36.7%
自由现金流更多
RBCAA
多$87.3M
$73.8M
两年增速更快
RBCAA
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $94.3M |
| 净利润 | $-54.6M | $22.8M |
| 毛利率 | 42.9% | — |
| 营业利润率 | -18.8% | 29.3% |
| 净利率 | -36.7% | 24.2% |
| 营收同比 | -23.6% | 5.3% |
| 净利润同比 | -74.4% | 20.0% |
| 每股收益（稀释后） | $-0.95 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSRBCAA
| Q4 25 | $148.7M | $94.3M | ||
| Q3 25 | $231.1M | $93.5M | ||
| Q2 25 | $140.9M | $93.8M | ||
| Q1 25 | $222.2M | $135.8M | ||
| Q4 24 | $194.7M | $89.5M | ||
| Q3 24 | $293.8M | $88.1M | ||
| Q2 24 | $254.7M | $86.9M | ||
| Q1 24 | $300.4M | $120.3M |
净利润EBSRBCAA
| Q4 25 | $-54.6M | $22.8M | ||
| Q3 25 | $51.2M | $29.7M | ||
| Q2 25 | $-12.0M | $31.5M | ||
| Q1 25 | $68.0M | $47.3M | ||
| Q4 24 | $-31.3M | $19.0M | ||
| Q3 24 | $114.8M | $26.5M | ||
| Q2 24 | $-283.1M | $25.2M | ||
| Q1 24 | $9.0M | $30.6M |
毛利率EBSRBCAA
| Q4 25 | 42.9% | — | ||
| Q3 25 | 62.8% | — | ||
| Q2 25 | 52.5% | — | ||
| Q1 25 | 60.2% | — | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | -18.8% | — | ||
| Q1 24 | 49.2% | — |
营业利润率EBSRBCAA
| Q4 25 | -18.8% | 29.3% | ||
| Q3 25 | 33.1% | 40.4% | ||
| Q2 25 | 1.1% | 43.0% | ||
| Q1 25 | 22.5% | 44.1% | ||
| Q4 24 | -4.9% | 25.8% | ||
| Q3 24 | 22.0% | 38.4% | ||
| Q2 24 | -79.9% | 37.0% | ||
| Q1 24 | 13.2% | 32.2% |
净利率EBSRBCAA
| Q4 25 | -36.7% | 24.2% | ||
| Q3 25 | 22.2% | 31.8% | ||
| Q2 25 | -8.5% | 33.5% | ||
| Q1 25 | 30.6% | 34.8% | ||
| Q4 24 | -16.1% | 21.2% | ||
| Q3 24 | 39.1% | 30.1% | ||
| Q2 24 | -111.2% | 29.0% | ||
| Q1 24 | 3.0% | 25.4% |
每股收益（稀释后）EBSRBCAA
| Q4 25 | $-0.95 | — | ||
| Q3 25 | $0.91 | — | ||
| Q2 25 | $-0.22 | — | ||
| Q1 25 | $1.19 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $2.06 | — | ||
| Q2 24 | $-5.38 | — | ||
| Q1 24 | $0.17 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $220.0M |
| 总债务越低越好 | $589.7M | — |
| 股东权益账面价值 | $522.6M | $1.1B |
| 总资产 | $1.3B | $7.0B |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资EBSRBCAA
| Q4 25 | $205.4M | $220.0M | ||
| Q3 25 | $245.5M | $484.2M | ||
| Q2 25 | $267.3M | $484.8M | ||
| Q1 25 | $149.1M | $793.0M | ||
| Q4 24 | $99.5M | $432.2M | ||
| Q3 24 | $149.9M | $530.9M | ||
| Q2 24 | $69.7M | $400.1M | ||
| Q1 24 | $78.5M | $546.4M |
总债务EBSRBCAA
| Q4 25 | $589.7M | — | ||
| Q3 25 | $693.1M | — | ||
| Q2 25 | $700.0M | — | ||
| Q1 25 | $700.0M | — | ||
| Q4 24 | $700.0M | — | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — | ||
| Q1 24 | $909.2M | — |
股东权益EBSRBCAA
| Q4 25 | $522.6M | $1.1B | ||
| Q3 25 | $582.5M | $1.1B | ||
| Q2 25 | $536.2M | $1.1B | ||
| Q1 25 | $552.7M | $1.0B | ||
| Q4 24 | $482.8M | $992.0M | ||
| Q3 24 | $508.4M | $979.7M | ||
| Q2 24 | $386.3M | $955.4M | ||
| Q1 24 | $663.9M | $935.6M |
总资产EBSRBCAA
| Q4 25 | $1.3B | $7.0B | ||
| Q3 25 | $1.5B | $7.0B | ||
| Q2 25 | $1.4B | $7.0B | ||
| Q1 25 | $1.4B | $7.1B | ||
| Q4 24 | $1.4B | $6.8B | ||
| Q3 24 | $1.5B | $6.7B | ||
| Q2 24 | $1.5B | $6.6B | ||
| Q1 24 | $1.8B | $6.9B |
负债/权益比EBSRBCAA
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — | ||
| Q1 24 | 1.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $161.1M |
| 自由现金流率自由现金流/营收 | 49.6% | 170.9% |
| 资本支出强度资本支出/营收 | 2.6% | 7.5% |
| 现金转化率经营现金流/净利润 | — | 7.37× |
| 过去12个月自由现金流最近4个季度 | $156.8M | $288.6M |
8季度趋势，按日历期对齐
经营现金流EBSRBCAA
| Q4 25 | $77.7M | $168.2M | ||
| Q3 25 | $-2.3M | $33.3M | ||
| Q2 25 | $106.4M | $8.4M | ||
| Q1 25 | $-11.2M | $93.2M | ||
| Q4 24 | $-79.9M | $149.0M | ||
| Q3 24 | $153.7M | $51.3M | ||
| Q2 24 | $47.5M | $4.0M | ||
| Q1 24 | $-62.6M | $71.2M |
自由现金流EBSRBCAA
| Q4 25 | $73.8M | $161.1M | ||
| Q3 25 | $-5.7M | $30.8M | ||
| Q2 25 | $103.5M | $5.2M | ||
| Q1 25 | $-14.8M | $91.6M | ||
| Q4 24 | $-81.6M | $143.2M | ||
| Q3 24 | $147.9M | $49.8M | ||
| Q2 24 | $42.9M | $2.7M | ||
| Q1 24 | $-73.4M | $69.1M |
自由现金流率EBSRBCAA
| Q4 25 | 49.6% | 170.9% | ||
| Q3 25 | -2.5% | 32.9% | ||
| Q2 25 | 73.5% | 5.5% | ||
| Q1 25 | -6.7% | 67.4% | ||
| Q4 24 | -41.9% | 160.0% | ||
| Q3 24 | 50.3% | 56.5% | ||
| Q2 24 | 16.8% | 3.1% | ||
| Q1 24 | -24.4% | 57.5% |
资本支出强度EBSRBCAA
| Q4 25 | 2.6% | 7.5% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 2.1% | 3.5% | ||
| Q1 25 | 1.6% | 1.2% | ||
| Q4 24 | 0.9% | 6.5% | ||
| Q3 24 | 2.0% | 1.7% | ||
| Q2 24 | 1.8% | 1.5% | ||
| Q1 24 | 3.6% | 1.7% |
现金转化率EBSRBCAA
| Q4 25 | — | 7.37× | ||
| Q3 25 | -0.04× | 1.12× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | -0.16× | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | 1.34× | 1.93× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | -6.96× | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RBCAA
暂无分部数据
